LEGN.O Shares Drop as 5-Day SMA is Crossed
Shares of LEGN.O declined sharply today, closing at $28.97, marking a notable downturn as the stock crossed below its 5-day simple moving average (SMA). This technical signal indicates increased bearish momentum, raising concerns among investors about the stock's near-term performance.
The recent activity in options trading further highlights market sentiment, with a $25.00 put contract showing a bid of 5 cents, suggesting a potential cost basis of $24.95, which is a 14% discount from the current price. This put option carries a 72% chance of expiring worthless, reflecting a cautious outlook among traders. Conversely, the $35.00 call contract, with a bid of 10 cents, offers a potential return of 21.16% if exercised, but also has a 71% chance of expiring worthless, indicating uncertainty in upward price movement.
Implied volatility remains high for both contracts, with the put at 73% and the call at 78%, compared to a trailing twelve-month volatility of 46%. This disparity suggests that investors are bracing for potential price swings, further complicating the stock's outlook as it navigates through these technical challenges.
Trade with 70% Backtested Accuracy
Analyst Views on LEGN
About LEGN
About the author

- Analyst Recommendations: Analysts from H.C. Wainwright and RBC Capital reiterated their buy ratings on Legend Biotech, propelling the stock to an 18% gain on Monday, sharply contrasting with the S&P 500's 0.2% decline.
- Price Target Increases: RBC's Leonid Timashev set a price target of $62 per share, while H.C. Wainwright's Mitchell Kapoor set a target of $50, reflecting optimistic market expectations for Legend's future performance.
- Industry Dynamics Impact: Eli Lilly's announcement of a potential $7 billion acquisition of clinical-stage oncology developer Kelonia Therapeutics sparked interest in Legend's future potential, particularly regarding its CAR-T cell therapy applications.
- R&D Progress: Kapoor noted that data from Legend's early-stage CD19/CD20 trial is expected to be published soon, and if successful, it could significantly enhance treatment options for certain cancers, further solidifying its position in the biotech sector.
- Analyst Optimism: Analysts from H.C. Wainwright and RBC Capital reiterated buy ratings for Legend Biotech, propelling the stock to an 18% gain on Monday, sharply contrasting with the S&P 500's 0.2% decline.
- Price Target Increases: Timashev set a price target of $62 per share while Kapoor set $50, reflecting strong analyst confidence in Legend's future performance, potentially attracting more investor interest.
- Positive Market Reaction: The announcement of Eli Lilly's acquisition of clinical-stage oncology developer Kelonia Therapeutics for up to $7 billion sparked excitement about Legend's future, particularly given its innovative CAR-T therapy science.
- Pipeline Progress: Kapoor noted that data from Legend's early-stage CD19/CD20 in vivo trial is expected to be published soon, and if successful, it could hold significant promise for treating certain cancers, further solidifying Legend's position in the biotech sector.
- Stock Surge: Legend Biotech (LEGN) shares rose 18% on Monday, marking its best day since April 2023, driven by Eli Lilly's acquisition of rival Kelonia Therapeutics, indicating strong market interest in CAR-T therapies.
- Acquisition Details: Eli Lilly's agreement with Kelonia is valued at up to $7 billion, including an upfront payment of $3.25 billion and milestone payments, with the transaction expected to close in the second half of 2026, further advancing CAR-T cell therapy development.
- Carvykti Sales Performance: Legend's CAR-T treatment Carvykti achieved profitability in 2025 with net sales of $1.9 billion and over 10,000 patients treated, demonstrating strong market demand and significant growth potential.
- Analyst Ratings Optimistic: RBC Capital reiterated an 'Outperform' rating with a $62 price target for Legend, projecting potential sales of $2.8 billion in 2026, reflecting analysts' confidence in the company's future growth trajectory.
- ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
- Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
- Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
- Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.











